NCT01506154 is a Phase 3 clinical trial of MRX-7EAT in Bursitis, sponsored by MEDRx USA, Inc..

Who is sponsoring NCT01506154?

NCT01506154 is sponsored by MEDRx USA, Inc..

What drugs are being tested in NCT01506154?

Interventions in NCT01506154: MRX-7EAT.

What condition does NCT01506154 study?

NCT01506154 studies Bursitis, Tendonitis, Shoulder Pain.

Is NCT01506154 still recruiting?

NCT01506154 is currently completed. Last updated 12 January 2018.

Last reviewed 2018-01-12 · How we verify

NCT01506154

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Topical Patch in the Treatment of Pain Due to Recent Onset Supraspinatous and/or Subacromial Tendonitis/Bursitis and/or Subdeltoid Bursitis of Shoulder

Completed Phase 3 Last updated 12 January 2018

What this trial tests

Phase 3 trial testing MRX-7EAT in Bursitis in 210 participants. Completed in 1 October 2012.

Timeline

1 December 2011

Primary endpoint
1 October 2012

1 October 2012

Quick facts

Lead sponsor	MEDRx USA, Inc.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	210
Start date	1 December 2011
Primary completion	1 October 2012
Estimated completion	1 October 2012
Sites	27 locations across United States

Drugs / interventions tested

MRX-7EAT — full drug profile →

Conditions studied

Bursitis — all drugs for Bursitis →
Tendonitis — all drugs for Tendonitis →
Shoulder Pain — all drugs for Shoulder Pain →

Sponsor

MEDRx USA, Inc. — full company profile →

Who can join

14 and older, any sex, with Bursitis or Tendonitis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Mean of all 16 Current Pain Intensity scores collected on Days 4 through 7 on a 0-10 NPRS.
Time frame: 7 days

Sponsor's own description

A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Pain due to Recent Onset Supraspinatous and/or Subacromial Tendonitis/Bursitis and/or Subdeltoid Bursitis of the Shoulder.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advances toward transformative therapies for tendon diseases.
Freedman BR, Mooney DJ, Weber E. · · 2022 · cited 28× · PMID 36070365 · DOI 10.1126/scitranslmed.abl8814

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01506154 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MEDRx USA, Inc.
Last refreshed: 12 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01506154.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing